Prophylaxis of respiratory syncytial virus (RSV)-infection in preterm infants with/without bronchopulmonary dysplasia: Hyperimmune globulin (RSV- IGIV) and palivizumab (MEDI-493);Prophylaxe der respiratory syncytial virus (RSV)-infektion bei fruhgeborenen mit/ohne bronchopulmonaler dysplasie: Hyperimmunglobulin (RSV- IGIV) und palivizumab (MEDI-493)

Klinische Padiatrie

Volumn 211, Issue 6, 1999, Pages 450-455

  Resch, Bernhard ^a   Müller, Wilhelm ^b  

^a Universitatsklinik fur Kinder und Jugendheilkunde Graz   (Austria)

^b NONE

Author keywords

Bronchopulmonary dysplasia; Palivizumab; Prematurity; Respiratory syncytial virus; Respiratory syncytial virus hyperimmune globulin

Indexed keywords

HYPERIMMUNE GLOBULIN; MONOCLONAL ANTIBODY; PALIVIZUMAB; UNCLASSIFIED DRUG;

ARTICLE; DISEASE ASSOCIATION; HUMAN; IMMUNOTHERAPY; INFANT; INFECTION PREVENTION; INFECTION RISK; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; PREMATURITY; PRESCHOOL CHILD; VIRUS PNEUMONIA;

EID: 0032725054     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1043832     Document Type: Article

References (30)

1. 1 American Academy of Pediatrics, Committees on Infectious Diseases and Fetus and Newborn. Respiratory syncytial virus immune globulin intravenous. Pediatrics 99 (1997) 645-650
2. 2 American Academy of Pediatrics: Use of RSV-IGIV and Palivizumab (a humanized monoclonal antibody product). Pediatrics 102 (1998) 1211-1216
3. 3 Besanko-Stead, K. L.: The impact and outcome of RSV disease in high-risk infants. Neonatal Intensive Care (1998) 20-21
4. 4 Chanock, R. M., B. Roizman, R. Myers: Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am. J. Hyg. 66 (1957) 281-290
5. 5 Chanock, R. M., H. W. Kim, J. Vargosko, A. DeLeva, K. M. Johnson, C. Cumming, R. H. Parrott: Respiratory syncytial virus. I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children. JAMA 176 (1961) 647-657
6. 6 Cunningham, C. K., J. A. McMillan, S. J. Gross: Rehospitalization for respiratory illness in infants less than 32 weeks' gestation. Pediatrics 88 (1991) 527-532
7. 7Glezen, W. P., L. H. Taber, A. L. Frank, J. A. Kasel: Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140 (1986) 543-546
8. 8 Groothuis, J. R., E. A. F. Simoes, M. J. Levin, C. B. Hall, C. E. Long, W. J. Rodriguez, J. Arrobio, H. C. Meissner, D. R. Fulton, R. C. Welliver, D. A. Tristram, G. R. Siber, G. A. Prince, M. Van Raden, V. G. Hemming, und die RSVIG Study Group: Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. New Engl. J. Med. 329 (1993) 1524-1530
9. 9 Hall, C. B.: Respiratory syncytial virus. In: Feigin, R. D., J. B. Cherry (eds.): Textbook of Pediatric Infectious Diseases, ed. 3, Philadelphia, PA, W. B. Saunders (1992) 1633-1656
10. 10 Hay, J. W., R. I. Ernst, H. C. Meissner: Respiratory syncytial virus immune globulin: A cost-effectiveness analysis. Am. J. Man. Care 2 (1996) 851-856
11. 11 Hemming, V. G., G. A. Prince, J. R. Groothuis, G. R. Siber: Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin. Microbiol. Rev. 8 (1995) 22-33
12. 12 Hemming, V. G., W. Rodriguez, H. W. Kim, C. D. Brandt, R. H. Parrott, B. Burch, G. A. Prince, P. A. Baron, R. J. Fink, G. Reaman: Intravenous immunoglobulin treatment of respiratory syncytial virus infection in infants and young children. Antimicrob. Agents Chemother. 31 (1987) 1882-1886
13. 13 Johnson, S., C. Oliver, G. A. Prince, V. G. Hemming, D. S. Pfarr, S. C. Wang, M. Dormitzer, J. O'Grady, S. Koenig, J. K. Tamura, R. Woods, G. Bansal, D. Couchenour, E. Tsao, W. C. Hall, J. F Young: Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176 (1997) 1215-1224
14. 14 Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, R. H. Parrott: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89 (1969) 422-434
15. 15 Langley, J. M, E. E. L. Wang, B. J, Law, D. Stephens, F. D. Boucher, S. Dobson, J. McDonald, N. E. McDonald, I. Mitchell, J. L. Robinson: Economic evaluation of respiratory syncytial virus infection in Canadian children. A Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J. Pediatr. 131 (1997) 113-117
16. 10 Meissner, H. C., D. R. Fulton, J. R. Groothuis, R. L. Geggel, G. R. Marx, V. G. Hemming, T. Hougen, D. R. Snydman: Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob. Agents Chemother. 37 (1993) 1655-1658
17. 17 Meissner, H. C., R. C. Welliver, S. A. Chartrand, D. R. Fulton, W. J. A. Rodriguez, J. R. Groothuis: Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Pediatr. Inf. Dis. J. 15 (1996) 1059-1068
18. 18 Meissner, H. C., J. R. Groothuis: Immunoprophylaxis and the control of RSV disease. Pediatrics 100 (1997) 260-263
19. 19 Morris, J. A., R. E. Blount, R. E. Savage: Recovery of cytopathogenic agent from chimpanzees with coryza. Proc. Soc. Exp. Biol. Med. 92 (1956) 544-549
20. 20 Oelberg, D., M. Reininger, J. V. Eeckhaut: A cost-benefit analysis of respiratory syncytial virus hyperimmune globulin (RSV-IGIV) in high-risk infants. Neonatal Intensive Care (1998) 29-33
21. 21 O'Shea, T. M., M. A. Sevick, L. B. Givner: Costs and benefits of respiratory syncytial virus immunoglobulin for lower respiratory tract illness in very low birth weight infants. Pediatr. Infect. Dis. J. 17 (1998) 587-593
22. 22 Prince, G. A., V. G. Hemming, R. L. Horswood, R. M Chanock: Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotlon rat. Virus Res. 3 (19985) 193-206
23. 23 Siber, G. R., J. Leszcynski, V. Pena-Cruz, C. Ferren-Gardner, R. Anderson, V. G. Hemming, E. E. Walsh, J. Burns, K. McIntosh, R. Gonin, L. J. Anderson: Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J. Infect. Dis. 165 (1992) 456-463
24. 24 Siber, G. R., D. Leombruno, J. Leszcynski, J. McIver, D. Bodkin, R. Gonin, C. M. Thompson, E. E. Walsh, P. A. Piedra, V. G. Hemming, G. A. Prince: Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J. Infect. Dis. 169 (1994) 1368-1373
25. 25 Simoes, E. A. F., H. M. Sondheimer, H. C. Meissner, R. C. Welliver, J. R. Groothuis: Respiratory syncytial virus in children with congenital heart disease. Pediatr. Res. 39 (1996) 113A
26. 26 Simoes, E. A. F, J. R, Groothuis, D. A. Tristram, K. Allessi, M. V. Lehr, G. R. Siber, R. C. Welliver: Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. J. Pediatr. 129 (1996) 214-219
27. 27 Subramanian, K. N. S., L. E. Weisman, T. Rhodes, R. Aragno, P. J. Sanchez, J. Steichen, L. B. Givner, T. L. Jennings, F. H Top, Jr., D. Carlin, E. Connor for the MEDI-493 Study Group: Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Inf. Dis. J. 17 (1998) 110-115
28. 28 The IMpact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102 (1998) 531-537
29. 29 The PREVENT study group: Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99 (1997) 93-99
30. 30 Weber, M. W., R. Dackour, S. Usen, G. Schneider, R. A. Adegbola, P. Cane, S. Jaffar, P. Milligan, B. M. Greenwood, H. Whittle, E. K. Mulholland: The clinical spectrum of respiratory syncytial virus disease in The Gambia. Pediatr. Infect. Dis. J. 17 (1998) 224-230